Business Wire

GE-HEALTHCARE

20.6.2022 09:02:12 CEST | Business Wire | Press release

Share
GE Healthcare Introduces Wireless Patient Monitoring Solution to Help Clinicians Detect Early Patient Deterioration

With most hospitals around the world currently relying on manual “spot-checks” to monitor patient vitals, GE Healthcare unveils Portrait Mobile3 , a wireless patient monitoring system that enables continuous monitoring throughout a patient’s stay. The system helps clinicians detect patient deterioration. Early detection of patient deterioration may help reduce length of stay and intensive care unit (ICU) admissions – and improve patient outcomes4 . Portrait Mobile includes patient-worn wireless sensors which communicate with a mobile monitor.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220616005149/en/

Globally, an estimated 65 percent of hospital patients and over 90 percent of post-acute care patients are monitored manually and not continually.5 Many vital sign changes are missed during spot checks which often occur in four-to-six-hour intervals6 . A UK national audit of adult in-hospital cardiac arrests showed that more than half (57 percent) occurred on the wards and only five percent in the ICU7 where patients are monitored continuously. Most patients who end up in cardiac arrest or critical care, don’t suddenly deteriorate but rather present with earlier vital signs that show abnormal trends8 . Respiratory rate is the highest ranked variable in models predicting clinical deterioration in the hospital9 .

With Portrait Mobile, respiration rate, oxygen saturation and pulse rate for general ward and post-surgery patients can be captured wirelessly, continuously. This innovation allows caregivers to identify changes that may signal that cardiorespiratory complications or infectious disease may be developing. It gives clinicians the opportunity to act early and potentially avert serious adverse events.

“In an evaluation clinical study conducted at a London hospital in the UK, 90 percent of nurses reported that they feel more reassured about their patient’s condition when continuous monitoring is used versus vital signs spot check measuring,” said Erno Muuranto, Engineering Director at GE Healthcare in Finland. “Portrait Mobile provides reliable measurement technology and meaningful alarms in a mobile setting.”

For patients, Portrait Mobile’s wireless continuous monitoring helps with the ability to move about the hospital, without being restricted to the bedside. This also allows visitors to interact with the patient without technology getting in the way. Moreover, the solution provides patients and family members peace of mind knowing that monitoring is constant - even when the patient is out of their room. Patient mobility may help improve patient outcomes and reduce length of stay, which may lower costs and elevate patient satisfaction10 .

Portrait Mobile is designed to be as reliable as wired technology. Its routable communications architecture enables hospitals to leverage their existing network infrastructure when deploying the system, reducing installation and maintenance costs.

Portrait Mobile was developed in Helsinki, GE Healthcare’s global center of excellence for monitoring solutions where engineers have been developing patient monitoring technology for decades. Today, GE monitors are used in hospitals across the world - from Beijing to London, New York, and more.

About GE Healthcare:

GE Healthcare is the $17.7 billion healthcare business of GE (NYSE: GE). As a leading global medical technology, pharmaceutical diagnostics and digital solutions innovator, GE Healthcare enables clinicians to make faster, more informed decisions through intelligent devices, data analytics, applications and services, supported by its Edison intelligence platform. With over 100 years of healthcare industry experience and around 48,000 employees globally, the company operates at the center of an ecosystem working toward precision health, digitizing healthcare, helping drive productivity and improve outcomes for patients, providers, health systems and researchers around the world.

Follow us on Facebook , LinkedIn , Twitter , Instagram and Insights for the latest news, or visit our website www.gehealthcare.com for more information.

_______________________
1 Taenzer, et al., Postoperative Monitoring—The Dartmouth Experience. The Official Journal of the Anesthesia Patient Safety Foundation; Volume 27, No. 1, 1-28 Circulation 94,429 (2012). 15. Brown, et al., Continuous Monitoring
2 https://www.medelahealthcare.com/en-GB/insights/benefits-of-early-patient-mobilization
3 Portrait Mobile is a CE-marked medical device. Portrait Mobile is not 510(k) cleared and not available in all markets.
4 Brown, et al., Continuous Monitoring in an Inpatient Medical-Surgical Unit: A Controlled Clinical Trial. The American Journal of Medicine; Vol. 127, Issue 3, 226–232. 16. Vincent, et al.,
5 https://www.managedhealthcareexecutive.com/view/need-continuous-monitoring-todays-healthcare-system
6 Michard, et al., Protecting ward patients. ICU Management & Practice; Vol 19 – Issue 1 (2019).
7 Nolan JP, Soar J, Smith GB, et al. (2014) Incidence and outcome of in-hospital cardiac arrest in the United Kingdom national cardiac arrest audit. Resuscitation, 2014; 85:987-92.
8 Churpek MM, Yuen TC, Huber MT, et al. (2012) Predicting cardiac arrest on the wards. A nested case-control study. Chest, 141:1170-1176.
9 Loughlin, et al., Respiratory Rate: The Forgotten Vital Sign – Make It Count! Jt Comm J Qual Patient Saf; 44(8) 494-499 (2018).
10 Vincent, et al., Improving detection of patient deterioration in the general hospital ward environment. Eur J Anaesthesiol; 35:325-333 (2018).

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release

The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t

Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release

The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a

SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release

Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye